Manufacturer of Controlled Substances; Notice of Registration, 4295-4296 [E7-1403]
Download as PDF
<![CDATA[
4295
ycherry on PROD1PC64 with NOTICES
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
likely impact of imports of Subject
Merchandise on the Domestic Industry.
(5) A list of all known and currently
operating U.S. producers of the
Domestic Like Product. Identify any
known related parties and the nature of
the relationship as defined in section
771(4)(B) of the Act (19 U.S.C.
1677(4)(B)).
(6) A list of all known and currently
operating U.S. importers of the Subject
Merchandise and producers of the
Subject Merchandise in the Subject
Countries that currently export or have
exported Subject Merchandise to the
United States or other countries since
the Order Dates.
(7) If you are a U.S. producer of the
Domestic Like Product, provide the
following information on your firm’s
operations on that product during
calendar year 2006 (report quantity data
in short tons and value data in U.S.
dollars, f.o.b. plant). If you are a union/
worker group or trade/business
association, provide the information, on
an aggregate basis, for the firms in
which your workers are employed/
which are members of your association.
(a) Production (quantity) and, if
known, an estimate of the percentage of
total U.S. production of the Domestic
Like Product accounted for by your
firm’s(s’) production;
(b) the quantity and value of U.S.
commercial shipments of the Domestic
Like Product produced in your U.S.
plant(s); and
(c) the quantity and value of U.S.
internal consumption/company
transfers of the Domestic Like Product
produced in your U.S. plant(s).
(8) If you are a U.S. importer or a
trade/business association of U.S.
importers of the Subject Merchandise
from the Subject Country(ies), provide
the following information on your
firm’s(s’) operations on that product
during calendar year 2006 (report
quantity data in short tons and value
data in U.S. dollars). If you are a trade/
business association, provide the
information, on an aggregate basis, for
the firms which are members of your
association.
(a) The quantity and value (landed,
duty-paid but not including
antidumping or countervailing duties)
of U.S. imports and, if known, an
estimate of the percentage of total U.S.
imports of Subject Merchandise from
each Subject Country accounted for by
your firm’s(s’) imports;
(b) the quantity and value (f.o.b. U.S.
port, including antidumping and/or
countervailing duties) of U.S.
commercial shipments of Subject
Merchandise imported from each
Subject Country; and
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
(c) the quantity and value (f.o.b. U.S.
port, including antidumping and/or
countervailing duties) of U.S. internal
consumption/company transfers of
Subject Merchandise imported from
each Subject Country.
(9) If you are a producer, an exporter,
or a trade/business association of
producers or exporters of the Subject
Merchandise in the Subject
Country(ies), provide the following
information on your firm’s(s’)
operations on that product during
calendar year 2006 (report quantity data
in short tons and value data in U.S.
dollars, landed and duty-paid at the
U.S. port but not including antidumping
or countervailing duties). If you are a
trade/business association, provide the
information, on an aggregate basis, for
the firms which are members of your
association.
(a) Production (quantity) and, if
known, an estimate of the percentage of
total production of Subject Merchandise
in each Subject Country accounted for
by your firm’s(s’) production; and
(b) the quantity and value of your
firm’s(s’) exports to the United States of
Subject Merchandise and, if known, an
estimate of the percentage of total
exports to the United States of Subject
Merchandise from each Subject Country
accounted for by your firm’s(s’) exports.
(10) Identify significant changes, if
any, in the supply and demand
conditions or business cycle for the
Domestic Like Product that have
occurred in the United States or in the
market for the Subject Merchandise in
the Subject Countries since the Order
Dates, and significant changes, if any,
that are likely to occur within a
reasonably foreseeable time. Supply
conditions to consider include
technology; production methods;
development efforts; ability to increase
production (including the shift of
production facilities used for other
products and the use, cost, or
availability of major inputs into
production); and factors related to the
ability to shift supply among different
national markets (including barriers to
importation in foreign markets or
changes in market demand abroad).
Demand conditions to consider include
end uses and applications; the existence
and availability of substitute products;
and the level of competition among the
Domestic Like Product produced in the
United States, Subject Merchandise
produced in the Subject Countries, and
such merchandise from other countries.
(11) (OPTIONAL) A statement of
whether you agree with the above
definitions of the Domestic Like Product
and Domestic Industry; if you disagree
with either or both of these definitions,
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
please explain why and provide
alternative definitions.
Authority: These reviews are being
conducted under authority of title VII of the
Tariff Act of 1930; this notice is published
pursuant to section 207.61 of the
Commission’s rules.
By order of the Commission.
Issued: January 25, 2007.
Marilyn R. Abbott,
Secretary to the Commission.
[FR Doc. E7–1446 Filed 1–29–07; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 20, 2006,
and published in the Federal Register
on September 29, 2006, (71 FR 57570),
Abbott Laboratories, DBA Knoll
Pharmaceutical Company, 30 North
Jefferson Road, Whippany, New Jersey
07981, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Dihydromorphine (9145) ...............
Hydromorphone (9150) .................
Schedule
I
II
The company plans to manufacture
bulk product and dosage units for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Abbott Laboratories to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Abbott Laboratories to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with State and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
E:\FR\FM\30JAN1.SGM
30JAN1
4296
Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices
Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–1403 Filed 1–29–07; 8:45 am]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
ycherry on PROD1PC64 with NOTICES
By Notice dated October 25, 2006 and
published in the Federal Register on
November 1, 2006, (71 FR 64298), Alcan
Packaging-Bethlehem, 2400 Baglyos
Circle, Bethlehem, Pennsylvania 18020,
made application to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Nabilone
(7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for
packaging and for distribution.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. § 823(a) and § 952(a)
and determined that the registration of
Alcan Packaging-Bethlehem to import
the basic class of controlled substance is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Alcan
Packaging-Bethlehem to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. § 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
FR Doc. E7–1399 Filed 1–29–07; 8:45 am]
BILLING CODE 4410–09–P
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 16,
2006, American Radiolabeled Chemical,
Inc., 101 Arc Drive, St. Louis, Missouri
63146, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Schedule
1–[1–(2–
Thienyl)cyclohexyl]piperidine;
TCP (7470).
Normorphine (9313) .....................
Dextropropoxyphene, bulk (nondosage form) (9273).
I
I
II
The company plans to manufacture
small quantities of the listed controlled
substances as radiolabeled compounds
for biochemical research.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than April 2, 2007.
Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–1385 Filed 1–29–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated October 11, 2006 and
published in the Federal Register on
October 18, 2006, (71 FR 61510–61511),
VerDate Aug<31>2005
15:36 Jan 29, 2007
Jkt 211001
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Boehringer Ingelheim Chemical, Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Phenylacetone (8501), a
basic class of controlled substance listed
in schedule II.
The company plans to import the
listed controlled substance to bulk
manufacture amphetamine.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. § 823(a) and § 952(a)
and determined that the registration of
Boehringer Ingelheim Chemical, Inc. to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Boehringer Ingelheim
Chemical, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. § 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–1400 Filed 1–29–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated September 20, 2006,
and published in the Federal Register
on September 29, 2006, (71 FR 57569),
Cambridge Isotope Lab, 50 Frontage
Road, Andover, Massachusetts 01810,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of Morphine (9300), a
basic class of controlled substance listed
in schedule II.
The company plans to utilize small
quantities of the listed controlled
substance in the preparation of
analytical standards.
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 72, Number 19 (Tuesday, January 30, 2007)]
[Notices]
[Pages 4295-4296]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-1403]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated September 20, 2006, and published in the Federal
Register on September 29, 2006, (71 FR 57570), Abbott Laboratories, DBA
Knoll Pharmaceutical Company, 30 North Jefferson Road, Whippany, New
Jersey 07981, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)...................... I
Hydromorphone (9150)........................ II
------------------------------------------------------------------------
The company plans to manufacture bulk product and dosage units for
distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Abbott Laboratories to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Abbott Laboratories to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
[[Page 4296]]
Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-1403 Filed 1-29-07; 8:45 am]
BILLING CODE 4410-09-P
